Durvalumab vs Sitagliptin

Durvalumab vs Sitagliptin: Overview

This comparison examines the pharmacological differences between Durvalumab and Sitagliptin.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Sitagliptin: DPP-4 inhibitor increasing incretin levels.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Sitagliptin — 12.4 hours.

Chemical Properties

Molecular Formula: Sitagliptin — C16H15F6N5O.

Molecular Weight: Sitagliptin — 407.3140 g/mol.

Type: Durvalumab — Antibody; Sitagliptin — Small molecule.